Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. Test size products are transitioning from 20 µl to 5 µl per test. Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 µl staining volume or per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Read more at www.biolegend.com/testsize regarding the test size change.
COA:
Cy3, Cy5, Cy5.5 and Cy7 are subject to proprietary rights of GE Healthcare Bio-Sciences Corp. and Carnegie Mellon University and made and sold under license from GE Healthcare Bio-Sciences Corp. Sale of this product is licensed for research use only.
PMA (50 ng/ml ) + ionomycin (1 µg/ml)-stimulated (6 hours + monensin, 2 µM) human peripheral blood lymphocytes intracellularly stained with BL168 PE/Cy7 and CD4 (RPA-T4) PE
IL-17A is the founding member of the IL-17 family, a group of six structurally related pro-inflammatory cytokines. IL-17A, secreted by activated CD4+ Th17 cell subpopulation, elicits multiple biological activities on a variety of cells including: the induction of IL-6, IL-8, G-CSF, and PGE2 production in epithelial, endothelial or fibroblasts; the enhancement of surface expression of ICAM-1 in fibroblasts; activation of NF-κB and costimulation of T cell proliferation. Recent studies demonstrated that, in mice, activated IL-17-secreting CD4+ helper T cells (Th17 cells) mediate an autoimmune arthritis that clinically and immunologically resembles rheumatoid arthritis (RA). Human IL-17A shows 63%, 63%, and 72% amino acid sequence identity to rat IL-17A, mouse IL-17A, and a protein encoded by the ORF13 gene of herpesvirus Saimiri (HVS), respectively.
Other Names:
Interleukin IL-17A, IL-17, Cytotoxic T lymphocyte-associated antigen 8 (CTLA-8)
Structure:
Cytokine; dimer; ~15 kD (Mammalian)
Cellular Sources:
Activated T cell subpopulation
Cellular Targets:
Fibroblasts, epithelial and endothelial cells, stromal cells
Receptors:
IL-17R
Bioactivity/Activities:
Secretion of IL-6, IL-8, G-CSF, prostaglandin E2 by epithelial, endothelial or fibroblastic cells; stimulates cell migration, cord formation, and IL-6 secretion by stromal cells
Antigen References:
1. Hirota K, et al. 2007. J. Exp. Med. 204:41. 2. Furuzawa-Carballeda J, et al. 2007. Autoimmun. Rev. 6:169. 3. Witowski J, et al. 2007. Kidney Int. 71:514. 4. Gaffen SL, et al. 2006. Vitam. Horm. 74:255. 5. Hymowitz S, et al. 2001. EMBO J. 20:5332.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.
Brilliant Violet 421™ anti-human IL-17A
Human peripheral blood lymphocytes were stimulated with PMA + Ionomycin for 6 hours (in the presence of monensin), stained with CD3 FITC, fixed, permeabilized, and then stained with IL-17A (clone BL168) Brilliant Violet 421™ (top) or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).
Purified anti-human IL-17A
PMA (50 ng/ml) + ionomycin (1 µg/ml)-stimulated (6 hours + monensin, 2 µM) human peripheral blood lymphocytes intracellularly stained with anti-IFNγ (4S.B3) PE and anti-IL-17A (BL168) FITC
FITC anti-human IL-17A
PMA (50 ng/ml) + ionomycin (1 µg/ml)-stimulated (6 hours + monensin, 2 µM) human peripheral blood lymphocytes were intracellularly stained with CD4 (RPA-T4) APC and anti-IL-17A (BL168) FITC.
Intracellularly stained anti-human IL-17A (BL168) FITC was blocked by purified B168.
PMA + ionomycin stimulated human peripheral blood lymphocytes were intracellularly stained with anti-IFN-γ (4S.B3) PE and IL-17A (BL168) FITC.
PE anti-human IL-17A
PMA (50 ng/ml) + ionomycin (1 µg/ml)-stimulated (6 hours + monensin, 2 µM) human peripheral blood lymphocytes intracellularly stained with CD3 (UCHT1) APC and anti-human IL-17A (BL168) PE
Alexa Fluor® 488 anti-human IL-17A
PMA (50 ng/ml ) + ionomycin (1 µg/ml)-stimulated (6 hours + monensin, 2 µM) human peripheral blood lymphocytes intracellularly stained with BL168 Alexa Fluor® 488 and CD3 (UCHT1) PerCP/Cy5.5
Alexa Fluor® 647 anti-human IL-17A
PMA (50 ng/ml ) + ionomycin (1 µg/ml)-stimulated (6 hours + monensin, 2 µM) human peripheral blood lymphocytes intracellularly stained with BL168 Alexa Fluor® 647 and CD3 (UCHT1) PE
Pacific Blue™ anti-human IL-17A
PMA (50 ng/ml) +ionomycin (1 µg/ml)-stimulated (6 hours + monensin, 2 µM) human peripheral blood lymphocytes intracellularly stained with BL168 Pacific Blue™ and CD3 (UCHT1) PerCP/Cy5.5
PerCP/Cy5.5 anti-human IL-17A
PMA (50 ng/ml ) + ionomycin (1 µg/ml)-stimulated (6 hours + monensin, 2 µM) human peripheral blood lymphocytes intracellularly stained with BL168 PerCP/Cy5.5 and CD3 (UCHT1) APC
PE/Cy7 anti-human IL-17A
PMA (50 ng/ml ) + ionomycin (1 µg/ml)-stimulated (6 hours + monensin, 2 µM) human peripheral blood lymphocytes intracellularly stained with BL168 PE/Cy7 and CD4 (RPA-T4) PE
Alexa Fluor® 700 anti-human IL-17A
PMA (50 ng/ml) + ionomycin (1 µg/ml)-stimulated (6 hours + monensin, 2 µM) human peripheral blood lymphocytes were intracellularly stained with CD4 (RPA-T4) PE and anti-human IL-17A (BL168) Alexa Fluor® 700, or blocked with purified BL168 then stained with BL168 Alexa Fluor® 700
APC/Cy7 anti-human IL-17A
PMA + ionomycin-stimulated (6 hours) human peripheral blood lymphocytes surface stained with CD3 FITC and then intracellularly stained with BL168 APC/Cy7 (top) or mouse IgG1, κ APC/Cy7 isotype control (bottom)
Brilliant Violet 570™ anti-human IL-17A
PMA + ionomycin-stimulated (6 hours) human peripheral blood lymphocytes (in the presence of monensin) were intracellularly stained with CD3 APC and anti-IL-17A (clone BL168) Brilliant Violet 570™ (top) or mouse IgG1, κ Brilliant Violet 570™ isotype control (bottom).
Brilliant Violet 605™ anti-human IL-17A
PMA + ionomycin-stimulated (6 hours) human peripheral blood lymphocytes (in the presence of monensin) were stained with CD3 FITC, fixed, permeabilized and then stained with IL-17A (clone BL168) Brilliant Violet 605™ (top) or mouse IgG1, κ Brilliant Violet 605™ isotype control (bottom).
